COMPASS Pathways Plc American Depository Shares (CMPS) vs Septerna (SEPN)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
COMPASS Pathways Plc American Depository Shares (CMPS) has outperformed Septerna (SEPN) over the past year, gaining 87.3% versus a gain of 71.3%. Septerna is the larger company by market cap ($1.68 billion vs $1.62 billion), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | CMPS | SEPN |
|---|---|---|
| Share price | $11.69 | $36.00 |
| Market cap | $1.62B | $1.68B |
| 1-day change | +1.12% | +0.93% |
| YTD return | +69.42% | +29.12% |
| 1-year return | +87.34% | +71.35% |
| 5-year return | -63.72% | — |
| EPS (TTM) | $-3.76 | $-0.54 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $15.87 | $51.10 |
| 52-week low | $4.88 | $17.55 |
| Distance from 52-week high | -26.34% | -29.55% |
| Analyst consensus | strong_buy | strong_buy |
| Avg. price target upside | +103.17% | +50.61% |
| Average volume | 3.13M | 383.90K |
| Shares outstanding | 138.48M | 46.68M |
| Employees | 156 | 123 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- CMPS has outperformed SEPN by 16.0 percentage points over the past year.
About COMPASS Pathways Plc American Depository Shares
CMPS stock →COMPASS Pathways plc operates as a biotechnology company that focuses on mental health in the United Kingdom and the United States. The company develops COMP360, a psilocybin therapy, which is in Phase III clinical trial for the treatment of treatment-resistant depression; and is in Phase II clinical trial for treating post-traumatic stress disorder and anorexia nervosa.
Health Care · Biotechnology: Pharmaceutical Preparations · 156 employees
About Septerna
SEPN stock →Septerna, Inc., a clinical-stage biotechnology company, discovers and develops G protein-coupled receptor (GPCR) oral small molecule products for the treatment of endocrinology, immunology and inflammation, and metabolic diseases. It develops PTH1R Program, oral small molecule Parathyroid Hormone 1 Receptor agonists for the treatment of hypoparathyroidism; SEP-631, an oral small molecule MRGPRX2 negative allosteric modulator (NAM) for chronic spontaneous urticaria and other mast cell diseases; and TSHR Program, an oral small molecule TSHR NAM for graves' disease and thyroid eye disease.
Health Care · Biotechnology: Pharmaceutical Preparations · 123 employees
CMPS vs SEPN FAQ
Which is bigger, COMPASS Pathways Plc American Depository Shares or Septerna?
Septerna (SEPN) is larger, with a market capitalization of $1.68B compared with $1.62B for COMPASS Pathways Plc American Depository Shares (CMPS).
Which stock has performed better over the past year, CMPS or SEPN?
CMPS returned +87.34% over the past 12 months, compared with +71.35% for SEPN (price return, excluding dividends). Past performance does not predict future results.
Are COMPASS Pathways Plc American Depository Shares and Septerna in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.